This is the number of patients worldwide living with chronic wounds.
This is the annual cost of chronic wound care in the United States.
This is the average treatment duration of a chronic wound.
Luxoderm was born from the research conducted by François Balembois at the Charles Fabry Laboratory, a joint research unit bringing together the Institut d’Optique Graduate School, CNRS, and Université Paris-Saclay. With a team of experts in optics and photonics, we innovate to provide healthcare professionals with advanced light-based solutions in dermatology and aesthetics.
Luxoderm designs a patented, non-invasive medical device that facilitates the transition from the inflammatory phase to the proliferative phase.It enables a simple, fast, and effective treatment of chronic wounds, usable by healthcare professionals both in hospitals and in patients’ homes, to enhance healing and improve quality of life.
Luxoderm relies on a scientific committee composed of experts in the medical field and photonics research, ensuring the excellence and innovation of our solutions.
Our founding team brings together diverse talents from five leading engineering and business schools. Together, we push the boundaries of technology in the service of dermatology.
Technological development within the Charles Fabry Laboratory, a joint research unit between the Institut d’Optique Graduate School, CNRS, and Université Paris-Saclay.
Completion of preclinical studies validating the device’s efficacy and development of the industrial version of the device.
First clinical investigation on humans within our partner hospitals and clinics.
Obtaining CE & FDA marking and launch of commercialization.
